Evonik stock: Jefferies cuts 2027 earnings view

Jefferies has taken a more cautious view of Evonik's earnings path. In a report published on Wednesday, November 11, and reviewed by Investing.com, the brokerage downgraded the specialty chemicals group to Hold from Buy and cut its 2027 EBITDA forecast by 9 percent to below 2 billion euros.

Jefferies Lowers Earnings Expectations

Jefferies said the earnings support from Middle East supply disruptions is fading. Methionine prices had fallen from their April peak by 43 percent in China, 31 percent in Europe and 15 percent in the United States, while European gas prices were at their highest level since November 2022.

The brokerage said Evonik's EBITDA was up 14 percent year to date, with Advanced Technologies up 25 percent and Custom Solutions approximately flat. It also expects the company to fall short of its 11 percent return-on-capital-employed target in 2029, forecasting 8.9 percent.

BASF Adds A Second Valuation Driver

Jefferies raised its price target to 21 euros from 20 euros, but said near-term share-price movements may depend more on potential engagement with BASF than on standalone fundamentals. It considers an offer above 27 euros increasingly difficult to justify because German site agreements limit available synergies.

Evonik's fourth-quarter results and 2027 guidance are scheduled for March 4, 2027. Those figures will show whether pricing, volumes and efficiency measures can offset weaker support from supply disruptions.

Evonik stock traded at 21.30 euros on Lang & Schwarz at 17:42 CET on Friday, November 13, 2026, 0.85 percent above the Xetra close of Friday, November 13, at 21.12 euros.

Broader market conditions remain relevant for German equities; see Current market reports.

More news and analyses on Evonik stock.